Author Archive

Drug Patent Expirations for May 17 2012

If your reader cannot render the information below, go to
http://www.DrugPatentWatch.com/innovation to see the latest expirations

<TD align=right–>
ADVERTISE
HERE
 
Who are the leading pharmaceutical patent challengers? A report on<br />
Paragraph IV challenges<!–/td>

This
newsletter is a free service of DrugPatentWatch

DrugPatentWatch offers comprehensive details on FDA approved drugs,
developers, and their patents

Simple flat-rate
database subscription plans

Ultimate
Plan
Premium Plan Basic Plan
One year $1,995 Subscribe $1,795 Subscribe $1,095 Subscribe
One month $525 Subscribe $425 Subscribe $325 Subscribe
48 hours $95 Subscribe $75 Subscribe
Plan
comparison
    Site
tour
    Contact





Drug Patent Expirations for May 17 2012

Tradename Applicant Generic Name Patent Number Patent Expiration
PLAVIX Sanofi Aventis
Us
clopidogrel bisulfate 4,847,265*PED May
17, 2012

*Drugs may be covered by multiple
patents or regulatory protections. See the DrugPatentWatch
database for complete details.







DrugPatentWatch Fills Your Competitive Intelligence
Needs

Subscribers have
access to valuable datasets, including:
  • Clinical trial information
  • International patent families
  • International patent priority and PCT
    information
  • Patent maintenance
  • Full-text patent downloads
  • Sales data (top 200 drugs)
  • Paragraph IV challenges
  • Tentative approvals
  • Dynamic search capabilities with data
    export
  • More…
See the Database
Preview
and Plan
Comparison
. Contact Us with any
questions.





The above list
does not discriminate between dominant and non-dominant patents. Drugs
listed above may be protected by additional patents and other regulatory
protections. See the DrugPatentWatch
database for complete details

DISCLAIMER:
Although great care is taken in the proper and correct provision of this
service, thinkBiotech LLC does not accept any responsibility for possible
consequences of errors or omissions in the provided information. There is
no warranty that the information contained herein is error free. Users of
this service are advised to seek professional advice and independent
confirmation before acting on any of the provided information. thinkBiotech
LLC reserves the right to amend, extend or withdraw any part or all of the
offered service without notice.
All trademarks and applicant names
are the property of their respective owners or
licensors.


Continue reading

Drug Patent Expirations for May 14 2012

If your reader cannot render the information below, go to
http://www.DrugPatentWatch.com/innovation to see the latest expirations

Pharmaceutical Industry Intelligence
ADVERTISE
HERE
 

This
newsletter is a free service of DrugPatentWatch

DrugPatentWatch offers comprehensive details on FDA approved drugs,
developers, and their patents

Simple flat-rate
database subscription plans

Ultimate
Plan
Premium Plan Basic Plan
One year $1,995 Subscribe $1,795 Subscribe $1,095 Subscribe
One month $525 Subscribe $425 Subscribe $325 Subscribe
48 hours $95 Subscribe $75 Subscribe
Plan
comparison
    Site
tour
    Contact





Drug Patent Expirations for May 14 2012

Tradename Applicant Generic Name Patent Number Patent Expiration
AGGRASTAT Medicure tirofiban
hydrochloride
5,292,756 May 14, 2012

*Drugs may be
covered by multiple patents or regulatory protections. See the DrugPatentWatch
database for complete details.







DrugPatentWatch Fills Your Competitive Intelligence
Needs

Subscribers have
access to valuable datasets, including:
  • Clinical trial information
  • International patent families
  • International patent priority and PCT
    information
  • Patent maintenance
  • Full-text patent downloads
  • Sales data (top 200 drugs)
  • Paragraph IV challenges
  • Tentative approvals
  • Dynamic search capabilities with data
    export
  • More…
See the Database
Preview
and Plan
Comparison
. Contact Us with any
questions.





The above list
does not discriminate between dominant and non-dominant patents. Drugs
listed above may be protected by additional patents and other regulatory
protections. See the DrugPatentWatch
database for complete details

DISCLAIMER:
Although great care is taken in the proper and correct provision of this
service, thinkBiotech LLC does not accept any responsibility for possible
consequences of errors or omissions in the provided information. There is
no warranty that the information contained herein is error free. Users of
this service are advised to seek professional advice and independent
confirmation before acting on any of the provided information. thinkBiotech
LLC reserves the right to amend, extend or withdraw any part or all of the
offered service without notice.
All trademarks and applicant names
are the property of their respective owners or
licensors.

Share this:


Continue reading

Drug Patent Expirations for May 11 2012

If your reader cannot render the information below, go to
http://www.DrugPatentWatch.com/innovation to see the latest expirations

<TD align=right–>
ADVERTISE
HERE
 
Who are the leading pharmaceutical patent challengers? A report on<br />
Paragraph IV challenges<!–/td>

This
newsletter is a free service of DrugPatentWatch

DrugPatentWatch offers comprehensive details on FDA approved drugs,
developers, and their patents

Simple flat-rate
database subscription plans

Ultimate
Plan
Premium Plan Basic Plan
One year $1,995 Subscribe $1,795 Subscribe $1,095 Subscribe
One month $525 Subscribe $425 Subscribe $325 Subscribe
48 hours $95 Subscribe $75 Subscribe
Plan
comparison
    Site
tour
    Contact





Drug Patent Expirations for May 11 2012

Tradename Applicant Generic Name Patent Number Patent Expiration
ALLEGRA Sanofi Aventis
Us
fexofenadine hydrochloride 6,187,791 May 11,
2012
ALLEGRA Sanofi
Aventis Us
fexofenadine hydrochloride 6,399,632 May 11,
2012
CHILDREN’S ALLEGRA
ALLERGY
Sanofi Aventis Us fexofenadine
hydrochloride
6,187,791 May 11, 2012
CHILDREN’S ALLEGRA ALLERGY Sanofi
Aventis Us
fexofenadine hydrochloride 6,399,632 May 11,
2012
CHILDREN’S ALLEGRA
HIVES
Sanofi Aventis Us fexofenadine hydrochloride 6,187,791 May 11,
2012
CHILDREN’S ALLEGRA
HIVES
Sanofi Aventis Us fexofenadine hydrochloride 6,399,632 May 11,
2012

*Drugs may be covered by multiple
patents or regulatory protections. See the DrugPatentWatch
database for complete details.







DrugPatentWatch Fills Your Competitive Intelligence
Needs

Subscribers have
access to valuable datasets, including:
  • Clinical trial information
  • International patent families
  • International patent priority and PCT
    information
  • Patent maintenance
  • Full-text patent downloads
  • Sales data (top 200 drugs)
  • Paragraph IV challenges
  • Tentative approvals
  • Dynamic search capabilities with data
    export
  • More…
See the Database
Preview
and Plan
Comparison
. Contact Us with any
questions.





The above list
does not discriminate between dominant and non-dominant patents. Drugs
listed above may be protected by additional patents and other regulatory
protections. See the DrugPatentWatch
database for complete details

DISCLAIMER:
Although great care is taken in the proper and correct provision of this
service, thinkBiotech LLC does not accept any responsibility for possible
consequences of errors or omissions in the provided information. There is
no warranty that the information contained herein is error free. Users of
this service are advised to seek professional advice and independent
confirmation before acting on any of the provided information. thinkBiotech
LLC reserves the right to amend, extend or withdraw any part or all of the
offered service without notice.
All trademarks and applicant names
are the property of their respective owners or
licensors.


Continue reading

Drug Patent Expirations for May 9 2012

If your reader cannot render the information below, go to
http://www.DrugPatentWatch.com/innovation to see the latest expirations

Journal of Commercial Biotechnology
ADVERTISE
HERE
 

This
newsletter is a free service of DrugPatentWatch

DrugPatentWatch offers comprehensive details on FDA approved drugs,
developers, and their patents

Simple flat-rate
database subscription plans

Ultimate
Plan
Premium Plan Basic Plan
One year $1,995 Subscribe $1,795 Subscribe $1,095 Subscribe
One month $525 Subscribe $425 Subscribe $325 Subscribe
48 hours $95 Subscribe $75 Subscribe
Plan
comparison
    Site
tour
    Contact





Drug Patent Expirations for May 9 2012

Tradename Applicant Generic Name Patent Number Patent Expiration
CRIXIVAN Merck Sharp
Dohme
indinavir sulfate 5,413,999 May 9,
2012

*Drugs may be covered by multiple
patents or regulatory protections. See the DrugPatentWatch
database for complete details.







DrugPatentWatch Fills Your Competitive Intelligence
Needs

Subscribers have
access to valuable datasets, including:
  • Clinical trial information
  • International patent families
  • International patent priority and PCT
    information
  • Patent maintenance
  • Full-text patent downloads
  • Sales data (top 200 drugs)
  • Paragraph IV challenges
  • Tentative approvals
  • Dynamic search capabilities with data
    export
  • More…
See the Database
Preview
and Plan
Comparison
. Contact Us with any
questions.





The above list
does not discriminate between dominant and non-dominant patents. Drugs
listed above may be protected by additional patents and other regulatory
protections. See the DrugPatentWatch
database for complete details

DISCLAIMER:
Although great care is taken in the proper and correct provision of this
service, thinkBiotech LLC does not accept any responsibility for possible
consequences of errors or omissions in the provided information. There is
no warranty that the information contained herein is error free. Users of
this service are advised to seek professional advice and independent
confirmation before acting on any of the provided information. thinkBiotech
LLC reserves the right to amend, extend or withdraw any part or all of the
offered service without notice.
All trademarks and applicant names
are the property of their respective owners or
licensors.


Continue reading

Drug Patent Expirations for May 6 2012

If your reader cannot render the information below, go to
http://www.DrugPatentWatch.com/innovation to see the latest expirations

Pharmaceutical Industry Intelligence
ADVERTISE
HERE
 

This
newsletter is a free service of DrugPatentWatch

DrugPatentWatch offers comprehensive details on FDA approved drugs,
developers, and their patents

Simple flat-rate
database subscription plans

Ultimate
Plan
Premium Plan Basic Plan
One year $1,995 Subscribe $1,795 Subscribe $1,095 Subscribe
One month $525 Subscribe $425 Subscribe $325 Subscribe
48 hours $95 Subscribe $75 Subscribe
Plan
comparison
    Site
tour
    Contact





Drug Patent Expirations for May 6 2012

Tradename Applicant Generic Name Patent Number Patent Expiration
TRAVATAN Z Alcon Pharms
Ltd
travoprost 6,503,497 May 6, 2012
TRAVATAN Z Alcon Pharms
Ltd
travoprost 6,849,253 May 6, 2012

*Drugs may be
covered by multiple patents or regulatory protections. See the DrugPatentWatch
database for complete details.







DrugPatentWatch Fills Your Competitive Intelligence
Needs

Subscribers have
access to valuable datasets, including:
  • Clinical trial information
  • International patent families
  • International patent priority and PCT
    information
  • Patent maintenance
  • Full-text patent downloads
  • Sales data (top 200 drugs)
  • Paragraph IV challenges
  • Tentative approvals
  • Dynamic search capabilities with data
    export
  • More…
See the Database
Preview
and Plan
Comparison
. Contact Us with any
questions.





The above list
does not discriminate between dominant and non-dominant patents. Drugs
listed above may be protected by additional patents and other regulatory
protections. See the DrugPatentWatch
database for complete details

DISCLAIMER:
Although great care is taken in the proper and correct provision of this
service, thinkBiotech LLC does not accept any responsibility for possible
consequences of errors or omissions in the provided information. There is
no warranty that the information contained herein is error free. Users of
this service are advised to seek professional advice and independent
confirmation before acting on any of the provided information. thinkBiotech
LLC reserves the right to amend, extend or withdraw any part or all of the
offered service without notice.
All trademarks and applicant names
are the property of their respective owners or
licensors.


Continue reading

Drug Patent Expirations for May 2 2012

If your reader cannot render the information below, go to
http://www.DrugPatentWatch.com/innovation to see the latest expirations

Pharmaceutical Industry Intelligence
ADVERTISE
HERE
 

This
newsletter is a free service of DrugPatentWatch

DrugPatentWatch offers comprehensive details on FDA approved drugs,
developers, and their patents

Simple flat-rate
database subscription plans

Ultimate
Plan
Premium Plan Basic Plan
One year $1,995 Subscribe $1,795 Subscribe $1,095 Subscribe
One month $525 Subscribe $425 Subscribe $325 Subscribe
48 hours $95 Subscribe $75 Subscribe
Plan
comparison
    Site
tour
    Contact





Drug Patent Expirations for May 2 2012

Tradename Applicant Generic Name Patent Number Patent Expiration
LIDODERM Teikoku Pharma
Usa
lidocaine 5,411,738 May 2, 2012
LIDODERM Teikoku Pharma
Usa
lidocaine 5,601,838 May 2, 2012

*Drugs may be
covered by multiple patents or regulatory protections. See the DrugPatentWatch
database for complete details.







DrugPatentWatch Fills Your Competitive Intelligence
Needs

Subscribers have
access to valuable datasets, including:
  • Clinical trial information
  • International patent families
  • International patent priority and PCT
    information
  • Patent maintenance
  • Full-text patent downloads
  • Sales data (top 200 drugs)
  • Paragraph IV challenges
  • Tentative approvals
  • Dynamic search capabilities with data
    export
  • More…
See the Database
Preview
and Plan
Comparison
. Contact Us with any
questions.





The above list
does not discriminate between dominant and non-dominant patents. Drugs
listed above may be protected by additional patents and other regulatory
protections. See the DrugPatentWatch
database for complete details

DISCLAIMER:
Although great care is taken in the proper and correct provision of this
service, thinkBiotech LLC does not accept any responsibility for possible
consequences of errors or omissions in the provided information. There is
no warranty that the information contained herein is error free. Users of
this service are advised to seek professional advice and independent
confirmation before acting on any of the provided information. thinkBiotech
LLC reserves the right to amend, extend or withdraw any part or all of the
offered service without notice.
All trademarks and applicant names
are the property of their respective owners or
licensors.


Continue reading

Drug Patent Expirations for Apr 25 2012

If your reader cannot render the information below, go to
http://www.DrugPatentWatch.com/innovation to see the latest expirations

Journal of Commercial Biotechnology
ADVERTISE
HERE
 

This
newsletter is a free service of DrugPatentWatch

DrugPatentWatch offers comprehensive details on FDA approved drugs,
developers, and their patents

Simple flat-rate
database subscription plans

Ultimate
Plan
Premium Plan Basic Plan
One year $1,995 Subscribe $1,795 Subscribe $1,095 Subscribe
One month $525 Subscribe $425 Subscribe $325 Subscribe
48 hours $95 Subscribe $75 Subscribe
Plan
comparison
    Site
tour
    Contact





Drug Patent Expirations for Apr 25 2012

Tradename Applicant Generic Name Patent Number Patent Expiration
NAVSTEL Alcon Pharms
Ltd
calcium chloride; dextrose; magnesium chloride; oxiglutatione;
potassium chloride; sodium bicarbonate; sodium chloride; sodium
phosphate
5,409,904 Apr 25, 2012
NAVSTEL Alcon Pharms
Ltd
calcium chloride; dextrose; magnesium chloride; oxiglutatione;
potassium chloride; sodium bicarbonate; sodium chloride; sodium
phosphate
5,578,578 Apr 25, 2012
OPTISON Ge Healthcare albumin
human
5,573,751 Apr 25, 2012

*Drugs may be
covered by multiple patents or regulatory protections. See the DrugPatentWatch
database for complete details.







DrugPatentWatch Fills Your Competitive Intelligence
Needs

Subscribers have
access to valuable datasets, including:
  • Clinical trial information
  • International patent families
  • International patent priority and PCT
    information
  • Patent maintenance
  • Full-text patent downloads
  • Sales data (top 200 drugs)
  • Paragraph IV challenges
  • Tentative approvals
  • Dynamic search capabilities with data
    export
  • More…
See the Database
Preview
and Plan
Comparison
. Contact Us with any
questions.





The above list
does not discriminate between dominant and non-dominant patents. Drugs
listed above may be protected by additional patents and other regulatory
protections. See the DrugPatentWatch
database for complete details

DISCLAIMER:
Although great care is taken in the proper and correct provision of this
service, thinkBiotech LLC does not accept any responsibility for possible
consequences of errors or omissions in the provided information. There is
no warranty that the information contained herein is error free. Users of
this service are advised to seek professional advice and independent
confirmation before acting on any of the provided information. thinkBiotech
LLC reserves the right to amend, extend or withdraw any part or all of the
offered service without notice.
All trademarks and applicant names
are the property of their respective owners or
licensors.


Continue reading

Drug Patent Expirations for Apr 22 2012

If your reader cannot render the information below, go to
http://www.DrugPatentWatch.com/innovation to see the latest expirations

<TD align=right–>
ADVERTISE
HERE
 
FDA Orange Book archives from 2005 to<br />
present<!–/td>

This
newsletter is a free service of DrugPatentWatch

DrugPatentWatch offers comprehensive details on FDA approved drugs,
developers, and their patents

Simple flat-rate
database subscription plans

Ultimate
Plan
Premium Plan Basic Plan
One year $1,995 Subscribe $1,795 Subscribe $1,095 Subscribe
One month $525 Subscribe $425 Subscribe $325 Subscribe
48 hours $95 Subscribe $75 Subscribe
Plan
comparison
    Site
tour
    Contact





Drug Patent Expirations for Apr 22 2012

Tradename Applicant Generic Name Patent Number Patent Expiration
TARGRETIN Eisai
Inc
bexarotene 6,043,279 Apr 22, 2012
TARGRETIN Eisai
Inc
bexarotene 6,320,074 Apr 22, 2012
TARGRETIN Eisai
Inc
bexarotene 7,655,699 Apr 22, 2012

*Drugs may be
covered by multiple patents or regulatory protections. See the DrugPatentWatch
database for complete details.







DrugPatentWatch Fills Your Competitive Intelligence
Needs

Subscribers have
access to valuable datasets, including:
  • Clinical trial information
  • International patent families
  • International patent priority and PCT
    information
  • Patent maintenance
  • Full-text patent downloads
  • Sales data (top 200 drugs)
  • Paragraph IV challenges
  • Tentative approvals
  • Dynamic search capabilities with data
    export
  • More…
See the Database
Preview
and Plan
Comparison
. Contact Us with any
questions.





The above list
does not discriminate between dominant and non-dominant patents. Drugs
listed above may be protected by additional patents and other regulatory
protections. See the DrugPatentWatch
database for complete details

DISCLAIMER:
Although great care is taken in the proper and correct provision of this
service, thinkBiotech LLC does not accept any responsibility for possible
consequences of errors or omissions in the provided information. There is
no warranty that the information contained herein is error free. Users of
this service are advised to seek professional advice and independent
confirmation before acting on any of the provided information. thinkBiotech
LLC reserves the right to amend, extend or withdraw any part or all of the
offered service without notice.
All trademarks and applicant names
are the property of their respective owners or
licensors.


Continue reading

Drug Patent Expirations for Apr 25 2012

If your reader cannot render the information below, go to
http://www.DrugPatentWatch.com/innovation to see the latest expirations

Journal of Commercial Biotechnology
ADVERTISE
HERE
 

This
newsletter is a free service of DrugPatentWatch

DrugPatentWatch offers comprehensive details on FDA approved drugs,
developers, and their patents

Simple flat-rate
database subscription plans

Ultimate
Plan
Premium Plan Basic Plan
One year $1,995 Subscribe $1,795 Subscribe $1,095 Subscribe
One month $525 Subscribe $425 Subscribe $325 Subscribe
48 hours $95 Subscribe $75 Subscribe
Plan
comparison
    Site
tour
    Contact





Drug Patent Expirations for Apr 25 2012

Tradename Applicant Generic Name Patent Number Patent Expiration
NAVSTEL Alcon Pharms
Ltd
calcium chloride; dextrose; magnesium chloride; oxiglutatione;
potassium chloride; sodium bicarbonate; sodium chloride; sodium
phosphate
5,409,904 Apr 25, 2012
NAVSTEL Alcon Pharms
Ltd
calcium chloride; dextrose; magnesium chloride; oxiglutatione;
potassium chloride; sodium bicarbonate; sodium chloride; sodium
phosphate
5,578,578 Apr 25, 2012
OPTISON Ge Healthcare albumin
human
5,573,751 Apr 25, 2012

*Drugs may be
covered by multiple patents or regulatory protections. See the DrugPatentWatch
database for complete details.







DrugPatentWatch Fills Your Competitive Intelligence
Needs

Subscribers have
access to valuable datasets, including:
  • Clinical trial information
  • International patent families
  • International patent priority and PCT
    information
  • Patent maintenance
  • Full-text patent downloads
  • Sales data (top 200 drugs)
  • Paragraph IV challenges
  • Tentative approvals
  • Dynamic search capabilities with data
    export
  • More…
See the Database
Preview
and Plan
Comparison
. Contact Us with any
questions.





The above list
does not discriminate between dominant and non-dominant patents. Drugs
listed above may be protected by additional patents and other regulatory
protections. See the DrugPatentWatch
database for complete details

DISCLAIMER:
Although great care is taken in the proper and correct provision of this
service, thinkBiotech LLC does not accept any responsibility for possible
consequences of errors or omissions in the provided information. There is
no warranty that the information contained herein is error free. Users of
this service are advised to seek professional advice and independent
confirmation before acting on any of the provided information. thinkBiotech
LLC reserves the right to amend, extend or withdraw any part or all of the
offered service without notice.
All trademarks and applicant names
are the property of their respective owners or
licensors.


Continue reading